Gina Columbus

Recent positive clinical trial data have provided the oncology community with several sequencing strategies for patients with EGFR-mutant non-small cell lung cancer.

Vassiliki A. Papadimitrakopoulou, MD, shares insight on how the lung cancer paradigm continues to evolve with the identification of targetable driver mutations, the challenges that remain, and the ongoing clinical trial efforts designed to better reach patients and improve their outcomes.

Immunotherapy should be given as a tailored, not blanket, treatment approach, especially for patients with lung cancer, according to Giorgio Scagliotti, MD, PhD.

Brock O’Neil, MD, discusses the struggles with treating localized bladder cancer in both the neoadjuvant and adjuvant settings, as well as the advancements with robotic cystectomy.

Sumanta Kumar Pal, MD, sheds light on the latest frontline therapeutic options for patients with mRCC and other advancements on the horizon.

Maura Dickler, MD, expands on the findings with abemaciclib presented at the 2018 ASCO Annual Meeting and what some of the next steps are for the CDK4/6 inhibitor.

Andy Hahn, MD, discusses the ongoing debate between abiraterone and docetaxel and the optimal patient selection for each agent in patients with metastatic hormone-sensitive prostate cancer.

Max Wicha, MD, shares insight on the intriguing research being conducted on breast cancer stem cells.

Key opinion leaders spoke with OncLive ahead of the 2018 ASCO Annual Meeting to share the top abstracts they believe could have the greatest impact on clinical practice and patient outcomes across lymphomas, gastrointestinal cancers, genitourinary cancers, and lung cancer.

Diane M. Simeone, MD, discusses the molecular complexities of pancreatic cancer, some of the commonly identified mutations, and ongoing clinical trial efforts that may be game changing for the field.

Eric A. Collisson, MD, speaks to the challenges and emerging advancements in cholangiocarcinoma and colon cancer.

A total 1.9% of more than 7.6 million current and former heavy smokers in the United States underwent lung cancer screening in 2016, suggesting that it remains inadequate despite USPTF recommendations.

Matthew Borst, MD, highlights the need for neoadjuvant therapy versus upfront surgery in newly diagnosed patients, effective treatment management for recurrent platinum-sensitive disease, and what to do in the third-line setting and beyond.

Saad Z. Usmani, MD, discusses the current state of immune checkpoint inhibitors in hematologic cancers, recent setbacks, and ongoing studies that could further shape the landscape.

Kelly McCann, MD, PhD, discusses the therapies available for patients with HER2-positive breast cancer and the potential benefit with additional subtyping in the field.

Sara Hurvitz, MD, shares insight on the 3 CDK4/6 inhibitors approved in HR-positive breast cancer, and looks toward the future of these agents, which will likely include combination strategies.

Helena A. Yu, MD, discusses sequencing strategies in EGFR-mutant NSCLC, the impact of osimertinib in the frontline setting, and the questions surrounding dacomitinib’s intriguing data in this landscape.

Neoadjuvant treatment with nivolumab demonstrated a 45% major pathologic response rate in patients with resectable stage I to III non–small cell lung cancer irrespective of PD-L1 expression.

William K. Kelly, DO, discusses the evolving imaging techniques and emerging therapeutic approaches in prostate cancer.

Leonard G. Gomella, MD, shares his insight on this year's expected advances in the field of prostate cancer.

ROS1, NTRK, MET, and HER2 are all less common molecular targets found in non–small cell lung cancer, but emerging therapeutic strategies are being explored to attack these abnormalities.

Upfront testing for BRAF V600E mutations is necessary for patients with non–small cell lung cancer, but if results are positive, physicians are unsure when to administer BRAF/MEK combination therapy—and they must be prepared to manage the associated adverse events.

Immune-based therapies continue to show promising signals for patients with small cell lung cancer and mesothelioma, but better predictive biomarkers are needed to determine who is most likely to benefit.

With durvalumab (Imfinzi) being hailed as a potentially practice changing therapy in locally advanced non–small cell lung cancer, ongoing studies are seeking to determine the efficacy of immunotherapy in earlier stages of disease.

Gilberto Lopes, MD, discusses the global disparities occurring in lung cancer care and some of the steps that are being taken to better serve patients with the available and emerging therapeutic approaches.

Erik P. Castle, MD, discusses the importance of risk stratifying low- and intermediate-risk localized prostate cancers.

Julie Graff, MD, shares her insight on pivotal trials exploring abiraterone acetate (Zytiga) and docetaxel in this in patients with castration-sensitive prostate cancer.

Matthew S. Davids, MD, discusses the key results of ibrutinib (Imbruvica) with standard frontline chemoimmunotherapy in CLL.

David Mason, MD, addresses the evolving role of surgery for patients with non–small cell lung cancer.

Kartik Konduri, MD, shares insight on molecular developments, recently discussed clinical trials, and steps the field needs to take to continue moving in a biomarker-driven paradigm of non–small cell lung cancer treatment.